Mindray Medical International Limited, commonly known as Mindray, is a leading global provider of medical devices and solutions, headquartered in Shenzhen, China (CN). Founded in 1991, the company has established a strong presence in key operational regions, including North America, Europe, and Asia, making significant strides in the healthcare industry. Specialising in innovative medical technologies, Mindray focuses on areas such as patient monitoring, in-vitro diagnostics, and ultrasound imaging. Its core products are distinguished by their advanced features and user-friendly designs, catering to the diverse needs of healthcare professionals. With a commitment to quality and innovation, Mindray has achieved notable milestones, including numerous industry awards and recognitions, solidifying its position as a trusted partner in healthcare worldwide.
How does Mindray's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Mindray's score of 37 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Mindray reported total carbon emissions of approximately 168.2 million kg CO2e, comprising 5,327,980 kg CO2e from Scope 1, 68,619,750 kg CO2e from Scope 2, and 94,210,380 kg CO2e from Scope 3 emissions. This data is cascaded from its parent company, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Mindray has set ambitious climate commitments, aiming for a 25% reduction in greenhouse gas (GHG) intensity for both Scope 1 and Scope 2 emissions by 2030, using 2021 as the baseline year. This target reflects the company's proactive approach to mitigating its environmental impact and aligns with industry standards for climate action. In 2023, the company reported total emissions of approximately 2,795,170 kg CO2e in the UK, with Scope 2 emissions at 25,700 kg CO2e and Scope 3 emissions at 2,769,470 kg CO2e. The previous year's global emissions were approximately 75.2 million kg CO2e, indicating a significant focus on reducing its carbon footprint across various operational scopes. Mindray's commitment to sustainability is evident in its structured reduction initiatives, which are essential for addressing the challenges of climate change and enhancing corporate responsibility in the biomedical sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 00,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mindray has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.